Study of MIBG with two drugs for high-risk neuroblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of targeted radiation (MIBG) with two medicines, vorinostat and dinutuximab, for children and young adults with high-risk neuroblastoma that has returned or not fully responded to earlier treatment. The goal is to see if adding these medicines helps the radiation work better and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age at least 1 year and no more than 31 years.
- Diagnosed with high-risk neuroblastoma, including if it was originally lower risk but became high risk.
- Disease that has come back (recurrent), not responded to treatment (refractory), or only partially responded (persistent) after at least 4 rounds of initial therapy.
- Tumor must show uptake on a MIBG scan.
- No prior allogeneic stem cell transplant (using donor cells) and no prior total body irradiation.
- Must never have received MIBG together with an anti-GD2 antibody (like dinutuximab) or a histone deacetylase inhibitor (like vorinostat).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial provides access to a radioactive medicine called 131I-MIBG for people with certain nerve tumors that have returned or not responded to standard treatment. The treatment targets and kills cancer cells, and it may help when other options have not worked.
This trial uses a radioactive medicine called MIBG to target and kill neuroblastoma or related tumor cells that have not responded to standard treatments. It may help patients whose cancer has come back or is hard to treat.
This trial gives a radioactive drug called 131-I-MIBG to treat neuroblastoma that has not gone away or has come back. The drug targets cancer cells, and stem cells are given back after treatment to help the body recover.
This trial studies a radioactive medicine called iodine I-131 MIBG to shrink tumors that take up MIBG. It may help people whose neuroblastoma or malignant pheochromocytoma/paraganglioma has come back, progressed, or not responded to standard treatment.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
This trial uses a radioactive medicine called 131I-MIBG to treat neuroblastoma or pheochromocytoma that has come back or not responded to standard treatment. The treatment targets and damages cancer cells while trying to spare healthy tissue.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.